As a continuation of previous research, fifteen bifendate derivatives bearing 6,7-dihydro-dibenzo [c,e]azepine scaffold were synthesized and evaluated as P-gp-medicated multidrug resistance (MDR) reversal agents. Biological evaluation indicated that compounds 6k and 9c more potently reversed P-gp-mediated MDR than bifendate and verapamil (VRP) by blocking P-gp mediated drug efflux function and not by decreasing P-gp expression in K562/A02 MDR cells. Interestingly, wound-healing and chamber migration assay showed that 6k and 9c could significantly attenuate the migration of MDA-MB-231 cells. Notably, 6k and 9c could markedly suppress the invasive activity of MDA-MB-231 cells, thus displayed potential anti-metastasis activity. Preliminary mechanism studies indicated that the anti-metastasis activity of 6k and 9c was associated with their inhibitory effect on the activity and expression of MMP-2 and MMP-9. These results, together with the MDR reversal results indicated that compounds 6k and 9c might be promising leads for developing novel anti-cancer agents with P-gp and tumor metastasis inhibitory activities.

作为先前研究的延续，合成了15个带有6,7-二氢-二苯并[c，e]氮杂pine骨架的联苯菊酯衍生物，并将其评估为P-gp药物多药耐药性（MDR）逆转剂。生物学评估表明，化合物6k和9c通过阻止P-gp介导的药物外排功能，而不是通过降低K562 / A02 MDR细胞中P-gp的表达，比联苯菊酯和维拉帕米（VRP）更有效地逆转P-gp介导的MDR。有趣的是，伤口愈合和小室迁移分析表明6k和9c可以显着减弱MDA-MB-231细胞的迁移。值得注意的是6k和9c可以显着抑制MDA-MB-231细胞的侵袭活性，从而显示出潜在的抗转移活性。初步的机理研究表明，6k和9c的抗转移活性与其对MMP-2和MMP-9的活性和表达的抑制作用有关。这些结果以及MDR逆转结果表明，化合物6k和9c可能是开发具有P-gp和肿瘤转移抑制活性的新型抗癌药的有希望的先导。